title: Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.
abstract: OBJECTIVE
  To compare the long-term outcome of photodynamic therapy (PDT) with that of intravitreal bevacizumab (IVB) for myopic choroidal neovascularizations (mCNVs).
  
  
  METHODS
  24 eyes were selected from 40 consecutive patients with mCNV, and the patients were divided into Group A, consisting of 12 eyes treated by PDT, and Group B, consisting of 12 eyes treated by 1.25 mg IVB. The age and best-corrected visual acuity (BCVA) were matched between the two groups. The BCVA, size of the chorioretinal atrophy surrounding the CNV (CRA), central foveal thickness (CFT) and CNV thickness were determined before and at 12 and 24 months after the treatment.
  
  
  RESULTS
  The BCVA did not change after PDT but was significantly improved from 0.75+/-0.25 to 0.49+/-0.42 logMAR units at 12 months and to 0.50+/-0.38 logMAR units at 24 months after IVB. The CFT were significantly reduced in both groups at 12 and 24 months. The CRAs were larger in group A than in group B at 12 and 24 months, and their sizes were correlated with the BCVA.
  
  
  CONCLUSIONS
  At 24 months, IVB is more effective than PDT in treating mCNV. The enlargement of the CRA might be related to the incomplete visual recovery after PDT.
authors: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan. babatakayuki@nifty.com
authors: Takayuki
authors: T
authors: Baba
authors: Mariko
authors: M
authors: Kubota-Taniai
authors: Masayasu
authors: M
authors: Kitahashi
authors: Kyoko
authors: K
authors: Okada
authors: Yoshinori
authors: Y
authors: Mitamura
authors: Shuichi
authors: S
authors: Yamamoto
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001284:Atrophy / Q000209:etiology / Q000503:physiopathology; D000068258:Bevacizumab; D002829:Choroid / Q000473:pathology; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D056965:Injections, Intraocular; D008875:Middle Aged; D009216:Myopia / Q000150:complications*; D010778:Photochemotherapy / Q000379:methods*; D012160:Retina / Q000473:pathology; D012189:Retrospective Studies; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab